Isis Pharmaceuticals Inc.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 15
drugs in development. Isis' drug development programs are aimed at treating
cardiovascular, metabolic and inflammatory diseases.
Isis' partners are
focused in disease areas such as inflammatory, ocular, viral and
neurodegenerative diseases, and cancer.
In its Ibis Biosciences division, Isis is developing and commercializing
the Ibis T5000 biosensor system, a revolutionary system to identify
infectious organisms. As an innovator in RNA-based drug discovery and
development, Isis is the owner or exclusive licensee of approximately 1,500
issued patents worldwide.